

Please note: all fields in **BOLD** are **REQUIRED** to prevent calls back to your facility.

Client Information

Account #: _____ **Account Name:** _____

Street Address: _____

City, ST, ZIP: _____

Phone: _____ **Fax:** _____

Additional Reporting Fax: _____

Requisition Completed by: _____ Date: _____

Ordering Physician (please print: Last, First): _____ **NPI #:** _____

Treating Physician (please print: Last, First): _____ NPI #: _____

The undersigned certifies that he/she is licensed to order the test(s) listed below and that such test(s) are medically necessary for the care/treatment of this patient. If ordering InVisionFirst®-Lung Liquid Biopsy, the undersigned additionally certifies that he/she understands Medicare's medical necessity criteria for the InVisionFirst®-Lung Liquid Biopsy test listed on the back of this form.

Authorized Signature: _____ **Date:** _____

Billing Information

Please include face sheet and front/back of patient's primary and secondary insurance cards.

Patient Status (Must Choose 1):

Hospital Patient (in) Medicare Insurance/Medicaid

Hospital Patient (out) Patient/Self-Pay

Non-Hospital Patient Bill charges to other Hospital/Facility:

ABN required for InVisionFirst®-Lung Liquid Biopsy on Medicare/Medicare Advantage patients who do not meet coverage criteria or when concurrent tissue/liquid biopsy testing is ordered (see back). ABN attached Yes No

Prior Authorization # _____ See the NeoGenomics.com Billing section for more info.

Clinical Information

Please attach patient's pathology report (required), clinical history, and other applicable report(s).

ICD-10 (Diagnosis) Code/Narrative (Required): _____

Reason for Referral: _____

New Diagnosis Relapse In Remission Monitoring

Staging: 0 I II III IIIA IIIB IV Note: _____

Mobile Phlebotomy Request ONCOLOGY OFFICE TO COMPLETE IF NEEDED

Patient Phone (mobile preferred): _____

Patient Email (optional): _____

Patient Home Address: _____

City, ST, ZIP: _____

Order Liquid Biopsy below and **please fax** this completed requisition, pathology report, and face sheet or insurance information to 239.690.4237.

By completing this section, Client represents it has obtained patient's consent to be contacted by third-party service.

NeoTYPE® Cancer Profiles

Comprehensive Genomic Profile (*pan-tumor, 336 biomarkers*)

Select tumor type for PD-L1 and HER2 matching

Breast

Lung

 → Reflex to InVisionFirst®-Lung Liquid Biopsy if tissue NGS is insufficient

Other

Targeted Profile

Breast

Colorectal

Lung

 → Reflex to InVisionFirst®-Lung Liquid Biopsy if tissue RNA and/or DNA is insufficient for NGS

Other Profile: _____

Please see back for available Profiles and write in Profile name

Patient Information

Last Name: _____ Male Female

First Name: _____ **M.I.** _____ Other Pt ID/Acct #: _____

Date of Birth: mm _____ / dd _____ / yyyy _____ Medical Record #: _____

By completing this section, Client represents it has obtained informed consent from patient to perform the services described herein.

3rd Party Specimen Location ONCOLOGY OFFICE TO COMPLETE

Client Services will request specimen from Pathology site.

Pathology Site: _____

Address: _____

Phone: _____ **Fax:** _____

Body Site: _____

Collection Date: mm _____ / dd _____ / yyyy _____

Specimen Information PATHOLOGY TO COMPLETE

Specimen ID: _____ **Block ID:** _____

Fixative/Preservative: _____ **Retrieved Date:** mm _____ / dd _____ / yyyy _____

Hospital Discharge Date: mm _____ / dd _____ / yyyy _____

Collection Date: mm _____ / dd _____ / yyyy _____ **Collection Time:** _____ AM PM

Primary Metastasis – If Metastasis, list Primary: _____

Slides # _____ Unstained _____ Stained _____ H&E _____

Paraffin Block(s) #: _____ **Choose best block** (for global molecular/NGS testing only). Submit ≤4 FFPE blocks. Blocks will be combined for molecular testing when necessary.

Peripheral Blood #: _____ *For all other testing, specify which block to use for each if sending multiple blocks. See back for details.*

Breast Marker & Gastric/GEA HER2 Fixation (CAP/ASCO Requirement)

Cold ischemic time ≤ 1 hour: Yes No Unknown

10% neutral buffered formalin: Yes No Unknown

HER2/ER/PgR Fixation duration 6 to 72 hours: Yes No Unknown

Liquid Biopsies

- InVisionFirst®-Lung Liquid Biopsy** (test upon receipt)
See InVisionFirst®-Lung Additional Information on back for ABN requirements.
- NeoLAB® Solid Tumor Liquid Biopsy**

Other Testing

- NTRK NGS Fusion Panel
 - RAS/RAF Panel
 - Other _____
 - Other _____
- Lung, Thyroid, or PIK3CA Breast Sponsored Testing Programs: separate requisitions required. Please see website.*

Specimen Requirements

Liquid biopsy tests InVisionFirst®-Lung Liquid Biopsy and NeoLAB® Solid Tumor Liquid Biopsy: Do not refrigerate. Special collection tubes and shipping requirements apply. Please contact Client Services for kits and see instructions provided in kit.

All other tests: Refrigerate specimen if not shipping immediately and use cool pack during transport.

Please call Client Services Team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 3. Please refer to the website for specific details on each specimen.

Additional Billing Information

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

1. Binding Service Order. This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.

2. Third Party Billing by NeoGenomics and Right to Bill Client. Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

NeoTYPE® Profile Assignments

Comprehensive & Targeted Breast, Colorectal, Lung

Selection	Profile to be Performed
Comprehensive	NeoTYPE Discovery for Solid Tumors*
Targeted Breast	NeoTYPE Breast*
Targeted Colorectal	NeoTYPE Colorectal*
Targeted Lung	NeoTYPE DNA & RNA - Lung

Other Targeted Profiles

Available Profiles	Please choose a NeoTYPE Profile and write its name on reverse				
Brain (DNA & RNA) with MGMT Promoter Methylation	Cervical*	Cholangiocarcinoma	Endometrial*	Esophageal*	Gastric* with MMR IHC
GI Predictive* with HER2 Colorectal	GIST & Soft Tissue	Head & Neck*	HRD+	Liposarcoma Fusion	Liver/Biliary*
Melanoma*	Other Solid Tumor*	Ovarian*	Pancreas*	Precision*	Thyroid*

PD-L1 IHC is included in all Profiles except Liposarcoma Fusion.

*Pan-TRK IHC in these Profiles will reflex to NTRK NGS Fusion Panel when indicated.

InVisionFirst®-Lung Liquid Biopsy Additional Information: Conditions for Medicare Coverage

InVisionFirst®-Lung Liquid Biopsy is a plasma-based, somatic comprehensive genomic profiling test (CGP) intended to assist physicians caring for patients with advanced (Stage IIIB/IV) non-small cell lung cancer (NSCLC). In accordance with Medicare's MoIDX Noridian LCD L37897, testing is appropriate under the following circumstances:

At diagnosis and untreated: When results for EGFR single nucleotide variants (SNVs) and insertions and deletions (indels); rearrangements in ALK and ROS1; and SNVs for BRAF are not available AND when tissue-based CGP is infeasible [i.e., quantity not sufficient (QNS) for tissue-based CGP or invasive biopsy is medically contraindicated] **OR**

At progression: For patients progressing on or after chemotherapy or immunotherapy who have not been tested for EGFR SNVs and indels; rearrangements in ALK and ROS1; and SNVs for BRAF, and for whom tissue-based CGP is infeasible; or for patients progressing on EGFR tyrosine kinase inhibitors (TKIs).

A signed ABN is required if patient does not meet the coverage criteria. ABN is also required if ordering InVisionFirst®-Lung Liquid Biopsy concurrently with tissue testing that includes EGFR, BRAF, ALK, and ROS1.

Additional Specimen Information

If submitting multiple blocks, client must indicate either "Choose best block (global molecular/NGS testing only)" or assign the selection of blocks to individual tests. If multiple blocks are sent without a selection, they will be held until clarification is provided. Please call Client Services Team with any questions regarding specimen information.

Test Descriptions

Please see complete test descriptions and all available tests at our website, www.neogenomics.com.

Test Notations

Specimen Usage: NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

NeoTYPE HER2 Reflex Default Pathways

Colorectal, GI Predictive	Reflex to HER2 Colorectal FISH if HER2 IHC is 3+ in 11-49% and/or 2+ in ≥ 50% of cells
Discovery, Endometrial, Ovarian, Pancreas	Reflex to HER2 (Other) w/Breast Scoring FISH if HER2 IHC is 2+
Other NeoTYPE Profiles	HER2 not included; does not apply

NeoTYPE® DNA & RNA Profiles - Brain or Lung

If the sample is insufficient to produce both DNA and RNA results, the available results will be reported and alternate CPT® Codes may apply. Please see website for details.

InVisionFirst®-Lung Liquid Biopsy

InVisionFirst®-Lung Liquid Biopsy testing is performed by Invata, Inc., a subsidiary of NeoGenomics Laboratories. See www.neogenomics.com for test details.

For our complete test menu, TATs, specimen requirements and more, please visit: www.neogenomics.com